The DESTINY-Breast02 trial evaluated T-DXd versus the physician’s choice treatment (trastuzumab/capecitabine or lapatinib/capecitabine) in patients with unresectable or metastatic HER2-positive breast cancer previously treated with T-DM1. This evidence concerns the gene ERBB2 and breast cancer.